Investment Rating - The report maintains a "BUY" rating for TK Group with a target price (TP) adjusted to HK$2.79, based on an 8.2x FY24E P/E ratio, which aligns with its 5-year historical forward P/E [2][20][34]. Core Insights - Management expressed a positive outlook on order restocking, new client acquisitions, and capacity expansion in Vietnam and Huizhou, particularly in the automotive, medical device, and e-cigarette sectors. Following a challenging FY23, net profit is expected to grow by 38% and 19% year-on-year in FY24 and FY25, respectively, driven by new orders and operational efficiency improvements [2][38]. - The stock is currently trading at 4.4x FY24E P/E with a yield of 10%, indicating an attractive risk/reward profile [2][38]. Financial Summary - FY23 revenue and net profit declined by 15% and 10% year-on-year, respectively, primarily due to weak demand in consumer electronics and communications, although the automotive and e-cigarette segments showed growth [38]. - Revenue projections for FY24E are set at HK$2,318 million, with a year-on-year growth of 19%, and net profit is expected to reach HK$282 million, reflecting a 38% increase [9][10][38]. - Gross profit margin improved to 26.4% in FY23 from 23.7% in FY22, attributed to favorable foreign exchange rates and easing supply chain issues in the automotive sector [38]. Revenue Breakdown - The revenue mix indicates a significant contribution from various segments, with mobile and wearable devices, medical devices, and automotive sectors being key growth drivers [6][9][10]. - The automotive segment is projected to grow by 25% in FY24E, while the e-cigarette segment is expected to continue its strong performance with a 40% growth forecast [9][10][38]. Valuation Metrics - The report highlights a P/E ratio of 4.4x for FY24E, which is considered attractive compared to historical averages, alongside a dividend payout ratio of 83% [2][38]. - The expected return on equity (ROE) is projected to improve to 16.0% in FY24E, reflecting enhanced profitability and operational efficiency [10][15][38].

Financial Performance - Revenue for the year ended December 31, 2023, was HKD 1,945,721, a decrease of 14.7% from HKD 2,279,321 in 2022[4] - Net profit for the year was HKD 204,191, down 10.0% from HKD 226,909 in the previous year[4] - Basic earnings per share decreased to HKD 0.25 from HKD 0.27, representing a decline of 7.4%[4] - The company's gross profit for the year was HKD 512,793 thousand, down from HKD 541,275 thousand in 2022[52] - The net profit for 2023 was HKD 204,191,000, a decrease of 10% from HKD 226,909,000 in 2022[56] - Basic earnings per share for 2023 was HKD 0.25, down from HKD 0.27 in 2022[56] - The group's revenue for the year ended December 31, 2023, was approximately HKD 1,945.7 million, a decrease of about HKD 333.6 million or 14.6% compared to HKD 2,279.3 million in 2022[71] - Gross profit for the year was approximately HKD 512.8 million, a decrease of about HKD 28.5 million or 5.3% from HKD 541.3 million in 2022, with a gross margin increase of 2.7 percentage points to 26.4%[73] - The net profit for the year was approximately HKD 204.2 million, a decrease of 10.0% from HKD 226.9 million in 2022, with a net profit margin increase of 0.5 percentage points to 10.5%[79] Dividends - Proposed final dividend per share is HKD 0.075, down from HKD 0.086 in 2022, and a special dividend of HKD 0.10 is proposed[4] - The company reported a basic earnings per share of HKD 7.5 for the final dividend, down from HKD 8.6 in 2022[37] - Total dividends paid in 2023 were HKD 94,991,000, maintaining the same amount as in 2022[58] - The board proposed a final dividend of HKD 0.075 per share and a special dividend of HKD 0.10 per share, subject to shareholder approval, totaling HKD 62,494,500 and HKD 83,326,000 respectively[159] - The total dividend for the year ended December 31, 2023, including an interim dividend of HKD 0.028 per share, amounts to HKD 0.203 per share[159] Assets and Liabilities - Current assets net value increased to HKD 1,193,086 from HKD 1,090,873, reflecting a growth of 9.4%[4] - Total liabilities decreased from HKD 1,091,928 thousand in 2022 to HKD 766,414 thousand in 2023, representing a reduction of approximately 29.7%[24] - The total equity and liabilities amounted to HKD 2,451,591 thousand as of December 31, 2023, compared to HKD 2,697,523 thousand in 2022[24] - The total equity of the group as of December 31, 2023, was approximately HKD 1,685.2 million, compared to HKD 1,605.6 million on December 31, 2022[109] Operational Efficiency - Gross margin improved to 26.4% from 23.7% in 2022, while net margin increased to 10.5% from 10.0%[4] - The current ratio improved to 276.0% from 219.1%, indicating better short-term financial health[4] - The return on equity decreased to 12.1% from 14.1%, while return on assets slightly decreased to 8.3% from 8.4%[4] - Inventory turnover days increased to 102 days from 98 days, indicating a slower inventory movement[4] - Trade receivables turnover days increased to 58 days from 54 days, while trade payables turnover days increased to 61 days from 57 days[4] - The group’s inventory turnover days as of December 31, 2023, were 102 days, an increase of 4 days from 2022, mainly due to an increase in long production cycle orders[110] - The group reported a trade receivables turnover of 58 days for the year ended December 31, 2023, an increase of 4 days compared to 2022, primarily due to sales growth to customers with credit terms between 60 to 90 days[137] - The trade payables turnover was 61 days for the year ended December 31, 2023, also an increase of 4 days compared to 2022, as some suppliers extended credit terms due to the group's good reputation[138] Business Segments - The injection molding component manufacturing business declined by 20.7% due to reduced overseas consumer demand, while the mold manufacturing business recorded a growth of 2.2% as global supply chains returned to normal[42] - Revenue from the automotive segment increased by 22.7% to HKD 368.7 million in 2023, compared to HKD 300.5 million in 2022[63] - Revenue from the injection molding components manufacturing segment decreased by 20.7% to HKD 1,326.1 million in 2023, compared to HKD 1,673.1 million in 2022[68] - The revenue from the mold manufacturing segment was approximately HKD 619.6 million, an increase of about HKD 13.4 million or 2.2% from HKD 606.2 million in 2022, accounting for approximately 31.8% of total revenue[80] - The revenue from the medical and personal care segment decreased by 18.0% due to reduced orders from personal care brand customers amid high inflation and interest rates[83] - The revenue from the electronic vaporizer segment increased by 63.4%, reflecting strong demand in the overseas market[83] Strategic Initiatives - The company plans to continue focusing on high-quality and cost-effective design solutions in the mold manufacturing sector, particularly for automotive and high-end consumer electronics[45] - The company aims to enhance product precision and expand its customer base in high-end sectors such as medical and consumer electronics[67] - The group plans to invest in capacity expansion and projects to capture potential growth in the future, primarily funded by internal resources[143] - The group has established an overseas production base in Vietnam to serve electronic consumer brand clients, aiming to expand production capacity gradually based on market demand[149] - The group is exploring the establishment of another production base in North America through acquisitions or investments to provide lower tariff-cost products and services[149] - The group is actively preparing to launch new products, integrating silicone with traditional injection molding technology to provide diverse product solutions[121] - The group plans to continue its diversification strategy and optimize internal organizational structure to enhance operational efficiency in response to economic uncertainties[123] Corporate Governance - The group emphasizes the importance of good corporate governance to maintain investor confidence and ensure sustainable growth[152] - The group has adhered to all provisions of the corporate governance code during the year ended December 31, 2023[153] Other Information - The company has adopted revised standards effective from January 1, 2023, which did not have a significant impact on the consolidated financial statements[28] - The company will suspend share transfer registration from May 28, 2024, to May 31, 2024, to determine eligibility for attending the annual general meeting and voting[160] - The company will also suspend share transfer registration from June 6, 2024, to June 7, 2024, for the proposed final and special dividends[166] - The annual report for the year ending December 31, 2023, will be sent to shareholders and published on the company's website[167]

Financial Performance - Profit for the period for the first half of 2023 was approximately HK$54.7 million, representing a decrease of approximately HK$3.8 million or 6.4% from approximately HK$58.5 million for the corresponding period in 2022[15]. - The Group's revenue for the first half of 2023 was HK$855.9 million, a decrease of 11.7% compared to HK$969.2 million in the same period of 2022[58]. - Profit for the period was HK$54.7 million, down 6.4% from HK$58.5 million in the first half of 2022[63]. - Basic earnings per share decreased to 6.6 HK cents, down 5.7% from 7.0 HK cents in the same period last year[63]. - Other income for the first half of 2023 was approximately HK$13.3 million, a decrease of 48.8% from HK$26.0 million in the same period of 2022[93]. - Net finance income for the first half of 2023 was approximately HK$3.8 million, down from HK$10.7 million in the same period of 2022, mainly due to increased interest expenses[95]. Profitability Metrics - The Group's gross profit margin for the first half of 2023 was 29.2%, an increase of 6.6 percentage points from 22.6% in the same period of 2022, due to cost reduction and efficiency improvement measures implemented over the past two years[2]. - The Group's gross profit increased by 10.4% to HK$199.7 million, with a gross profit margin rising by 4.6 percentage points to 23.3%[66]. - The gross profit margin increased to 23.3%, up 4.6 percentage points from 18.7% in the corresponding period last year, due to enhanced capabilities and cost reduction measures[112]. - The gross profit margin for the mold fabrication segment increased by 6.6 percentage points to 29.2% in the first half of 2023, up from 22.6% in the same period of 2022[90]. - The gross profit margin for the plastic components manufacturing segment rose by 3.4 percentage points to 20.7%, attributed to cost reduction efforts and falling raw material prices[92]. Revenue Breakdown - The Group's sales in the mobile and wearable devices and smart home sectors decreased by 24.4% and 38.6%, respectively, compared to the same period last year[11]. - Revenue from the mold fabrication business increased by approximately 6.5% to HK$263.2 million, accounting for approximately 30.8% of the Group's total revenue[70]. - Revenue from the plastic components manufacturing segment generated approximately HK$592.7 million, down 17.9% year-on-year, accounting for about 69.2% of the Group's total revenue[86]. - Revenue from the medical and personal health care segment experienced an 18.4% decline in revenue, primarily due to reduced orders from customers in the U.S. and Europe, although domestic medical customer revenue increased[87]. - Revenue from electronic vaporizer products increased by 93.2% year-on-year, reflecting strong demand in overseas markets[109]. Equity and Financial Position - Total equity of the Group as of June 30, 2023, was approximately HK$1,526.4 million, down from HK$1,605.6 million as of December 31, 2022[16]. - The gearing ratio as of June 30, 2023, was approximately 11.3%, a decrease from 21.6% as of December 31, 2022, primarily due to a reduction in bank borrowings[16]. - Net current assets as of June 30, 2023, were HK$1,050.7 million, compared to HK$1,090.9 million at the end of 2022[52]. - The current ratio as of June 30, 2023, was approximately 231.3%, an increase from 219.1% as of December 31, 2022[131]. - The Group maintained a high level of net cash at HK$935.7 million, a year-on-year increase of 24.6%[68]. Operational Efficiency - The Group is focusing on cost reduction and efficiency improvement measures to enhance production efficiency and management effectiveness[63]. - The Group has implemented employee training programs to enhance productivity in response to various job requirements[10]. - The Group is focusing on internal optimization, technological upgrades, and adopting Industry 4.0 to enhance operational efficiency and reduce costs[186]. - The Group's inventory turnover days decreased to 116 days, a reduction of 7 days compared to the same period last year, reflecting improved logistics and transportation[105]. - Trade receivable turnover days decreased to 61 days, down 2 days from the previous year, indicating effective credit policies[139]. Market and Strategic Developments - The Group has successfully established overseas production bases in Vietnam to provide supply solutions outside of China and is actively developing new customers in Southeast Asia and Europe[21]. - The newly developed medical business has gradually become a new growth point for the Group, focusing on innovative product solutions using silicone integration technology[21]. - The Group aims to develop optical silicone components to meet the demand for light output capabilities in Mini LED display parts, targeting a "blue ocean" market[21]. - The Group's mold business benefited from the gradual recovery in the automotive industry, with a significant increase in order volume[72]. - The group plans to invest in capacity expansion and projects to capitalize on potential growth opportunities in the coming years[146]. Shareholder Information - As of June 30, 2023, Eastern Mix holds 357,014,000 shares, representing 42.85% of the issued share capital[192]. - Lead Smart Development Limited owns 89,400,000 shares, accounting for 10.73% of the issued share capital[192]. - Cheer Union Development Ltd. has 55,620,000 shares, which is 6.67% of the issued share capital[192]. - Normal Times International Limited holds 53,640,000 shares, representing 6.44% of the issued share capital[192]. - FMR LLC has an interest in controlled corporations amounting to 49,212,000 shares, or 5.91% of the issued share capital[192]. - FIL Limited and its affiliates collectively hold 249,726,000 shares, representing 9.99% of the issued share capital[192]. - Brown Brothers Harriman & Co. holds 42,716,200 shares, which is 5.13% of the issued share capital[192]. - The company purchased 1,930,000 shares for its share award scheme during the six months ended June 30, 2023[196]. Compliance and Governance - The company complied with all code provisions as set out in the CG Code during the six months ended June 30, 2023[199]. - No major subsequent events affecting the Group have occurred since the end of the period[197].

| --- | --- | |-----------|-----------| | 126,583 | 176,118 | | | | | 342,548 | 348,601 | | 261,358 | 200,955 | | 4,670 | 4,405 | | 148,191 | 286,472 | | 43,208 | 75,377 | | | | | | | | 799,975 | 915,810 | | | | | 926,558 | 1,091,928 | | | | | 2,452,916 | 2,697,523 | – 6 – 於2013年12月20日，本 公 司 完 成 公 開 發 售，本 公 司 的 股 份 在 香 港 聯 合 交 易 所 有 限 公 司（「聯交所」）上 市。 2. 編製基準 3.1 本集團採納的新訂及經修訂準則 – 7 – 5. 分部資料 | --- | --- | --- | --- | --- | --- | --- | |----------------|--------------------|-----------|------------------------ ...

Revenue Performance - Revenue from mold fabrication in 2022 was HK$606,235,000, a decrease from HK$706,025,000 in 2021[21] - Revenue from plastic components manufacturing in 2022 was HK$1,673,086,000, slightly down from HK$1,698,373,000 in 2021[21] - Total revenue for 2022 was HK$2,279,321,000, compared to HK$2,404,398,000 in 2021[21] - Revenue for 2022 was HK$2,279.3 million, a year-on-year decrease of 5.2%[31] - Total revenue for 2022 was HK$2,279.3 million, a year-on-year decrease of 5.2% compared to HK$2,404.4 million in 2021[61] - Revenue from the mold fabrication business decreased by 14.1% due to instability in the automobile supply chain[61] - Revenue from mobile phones and wearable devices decreased by 19.4% to HK$648.2 million, accounting for 28.4% of total revenue[82] - Medical and personal health care revenue increased by 3.6% to HK$426.5 million, representing 18.7% of total revenue[82] - Smart home revenue grew by 7.7% to HK$330.6 million, contributing 14.5% to total revenue[82] - Automobiles revenue declined by 33.5% to HK$300.5 million, making up 13.2% of total revenue[82] - Commercial telecommunications equipment revenue surged by 72.1% to HK$293.1 million, accounting for 12.9% of total revenue[82] - Mold fabrication segment revenue decreased by 14.1% to HK$606.2 million, representing 26.6% of total revenue[87] - Plastic component manufacturing revenue slightly decreased by 1.5% to HK$1,673.1 million, accounting for 73.4% of total revenue[91] - Total revenue for 2022 was HK$2,279.3 million, a year-on-year decrease of 5.2%[98] - Mold fabrication business revenue decreased by 14.1% due to automotive supply chain instability[98] - Plastic components manufacturing revenue slightly decreased by 1.5% to HK$1,673.1 million, accounting for 73.4% of total revenue[109] - Revenue from external customers of the plastic components manufacturing segment decreased by HK$25.3 million (1.5%) to HK$1,673.1 million in 2022 compared to HK$1,698.4 million in 2021[117] - Revenue from the mold fabrication segment decreased by HK$99.8 million (14.1%) to HK$606.2 million in 2022 from HK$706.0 million in 2021, affected by supply chain disruptions and semiconductor shortages[142] - Revenue for 2022 was HK$2,279.3 million, a decrease of HK$125.1 million or 5.2% compared to 2021[188] - The company's revenue for the year ended December 31, 2022, was approximately HKD 2,279.3 million, a decrease of HKD 125.1 million or 5.2% compared to 2021[197] Profit and Profit Margins - Net profit for 2022 was HK$227 million, maintaining above HK$200 million for the past four years[26] - Net profit margin remained above 10% despite challenging business conditions[26] - Profit for the year was HK$226.9 million, a decrease of 19.6% compared to the previous year[31] - Net profit margin decreased to 10.0% from 11.7% in 2021[31] - Profit for 2022 was HK$226.9 million, a decrease of 19.6% from the previous year[67] - Net profit for the year dropped by 19.6% to HK$226.9 million, with net profit margin decreasing by 1.7 percentage points to 10.0%[85] - Profit for 2022 was HK$226.9 million, a decrease of HK$55.5 million or 19.6% compared to 2021[158][168] Gross Profit and Margins - Gross profit margin remained stable at 23.7%[31] - Gross profit margin for the first half of 2022 fell to 18.7% from 23.7% in the same period last year due to semiconductor shortages[84] - Full-year gross profit decreased by 4.9% to HK$541.3 million, with gross profit margin remaining stable at 23.7%[84] - Gross profit margin for the mold fabrication segment decreased by 0.7 percentage points to 26.4%[106] - Gross profit margin for plastic components manufacturing increased by 0.6 percentage points to 22.8%[113] - Gross profit for 2022 was HK$541.3 million, a decrease of HK$27.9 million (4.9%) from HK$569.2 million in 2021, with gross profit margin remaining stable at 23.7%[119] - The mold fabrication segment's gross profit margin decreased by 0.7 percentage points to 26.4% in 2022 from 27.1% in 2021, impacted by global semiconductor shortages and Euro depreciation[120] - The plastic components manufacturing segment's gross profit margin increased by 0.6 percentage points to 22.8% in 2022 from 22.2% in 2021, driven by improved order stability and internal production efficiency[146] - Gross profit for 2022 was HK$541.3 million, a decrease of HK$27.9 million or 4.9% compared to 2021, with a gross margin of 23.7%, unchanged from 2021[189] Cash and Financial Position - Net cash as of 31 December 2022 was HK$924,579,000, up from HK$864,067,000 in 2021[16] - Net cash increased by 7.0% to HK$924.6 million, maintaining a strong cash position[101] - The Group's net current assets as of 31 December 2022 were HK$1,090.9 million, with total cash and bank balances of HK$1,271.6 million, including HK$1,114.5 million in cash and cash equivalents[158][169] - The Group's current ratio as of 31 December 2022 was 219.1%, a decrease of 1.6 percentage points from 2021[160][182] - The Group's total equity as of 31 December 2022 was HK$1,605.6 million, with a gearing ratio of 21.6%, compared to HK$1,621.9 million and 20.9% in 2021[134] - The Group's total equity as of 31 December 2022 was HK$1,605.6 million, with a debt-to-equity ratio of 21.6%, up from 20.9% in 2021[172] Dividends - The company proposed a final dividend of 8.6 HK cents per share, maintaining the same level as the previous year[31] - The dividend payout ratio for 2022 was 41.9%, with a total annual dividend of 11.4 HK cents per share[50] - The Board recommended a dividend payout ratio of 41.9%, with a final dividend of HK8.6 cents per share and a total dividend payout of HK11.4 cents per share for the year[67] Business Expansion and Strategy - The company expects recovery and rapid growth in 2023 as the impact of the epidemic dissipates[23] - The company has invested in new products and industries, exploring new business directions for sustainable growth[26] - The company established a production base in Vietnam to meet increasing demand and expand capacity[54] - The company is focusing on developing domestic leading enterprises to tap into the huge domestic demand market in China[54] - The company continues to seek suitable acquisition or investment targets to expand its business scope and industrial advantages[54] - The company maintains a strong focus on innovation and change, aiming to strengthen its position in the plastic injection molding industry chain[55] - The company aims to double the scale of its plastic injection molding business as part of its five-year plan set in 2020[70] - The company successfully entered the medical testing consumables and electronic atomizers industries, which have low seasonal and economic cyclical sensitivity[71] - The company has developed a product solution integrating liquid silicone and traditional plastic injection molding technology, improving product design, comfort, and functionality[71] - The company has established a production base in Vietnam and plans to expand capacity to meet increasing demand[56] - The company is focusing on developing domestic market opportunities in China and supporting Chinese brands in international markets[56] - The company is actively seeking acquisition or investment opportunities to expand its business and industry advantages[56] Segment Performance - Commercial telecommunications equipment segment revenue increased significantly by 72.1% year-on-year[111] - Electronic atomizers segment revenue grew by 27.0% year-on-year[111] - Smart home and medical & personal care segments saw steady revenue growth of 7.7% and 3.6% respectively[112] - The commercial communication equipment segment revenue increased significantly by 72.1% year-on-year, driven by successful customer business transformation and new product launches[138] - The smart home segment and medical/personal health care segment achieved stable revenue growth, with year-on-year increases of 7.7% and 3.6% respectively[195] Expenses and Other Financial Metrics - Administrative expenses for 2022 were HK$280.6 million, a 13.6% increase from 2021, accounting for 12.3% of total revenue, up 2.0 percentage points[152][154] - Sales expenses for the year ended December 31, 2022, were approximately HKD 67.0 million, a decrease of HKD 12.3 million or 15.4% compared to 2021, accounting for 2.9% of total revenue, down 0.4 percentage points from 2021[198] - Other income for 2022 decreased by HK$7.3 million (14.0%) to HK$44.6 million from HK$51.9 million in 2021, mainly due to reduced sales of scrap and surplus materials[147] - Net finance income for 2022 decreased by HK$4.7 million (26.4%) to HK$13.4 million from HK$18.1 million in 2021, primarily due to increased interest expenses[131] - Trade receivable turnover days increased to 54 days in 2022, up 4 days from 2021, due to increased sales to domestic customers with credit periods of 60 to 90 days[160][165] - Trade payable turnover days decreased to 57 days in 2022, down 5 days from 2021, due to reduced procurement and lower trade payables balance[160][181] - The company's inventory turnover days remained unchanged at 98 days compared to 2021[200]

Financial Performance - Total revenue for 2022 was HKD 2,279,321,000, a decrease of 5.2% from HKD 2,404,398,000 in 2021[7] - Net profit for 2022 was HKD 226,909,000, down 19.6% from HKD 282,383,000 in 2021[7] - Basic earnings per share for 2022 was HKD 0.27, compared to HKD 0.34 in 2021, reflecting a decline of 20.6%[4] - Gross profit for the year was HKD 541,275,000, compared to HKD 569,167,000 in 2021, reflecting a decline of 4.9%[31] - Other income for the year ended December 31, 2022, was approximately HKD 44.6 million, a decrease of 14.0% from HKD 51.9 million in 2021[80] - Profit for the year ended December 31, 2022, was approximately HKD 226.9 million, down 19.6% from HKD 282.4 million in 2021[136] Profitability Ratios - Net profit margin decreased to 10.0% in 2022 from 11.7% in 2021[7] - Return on equity (ROE) fell to 14.1% in 2022 from 17.4% in 2021[7] - The gross profit margin for the injection molding business improved by 0.6 percentage points to 22.8% compared to 22.2% in 2021[74] Assets and Liabilities - Total assets decreased to HKD 2,697,523,000 in 2022 from HKD 2,851,160,000 in 2021[22] - The group reported a total debt of HKD 1,091,928,000, down 11.2% from HKD 1,229,241,000 in the previous year[24] - The group’s total liabilities decreased by 11.2% from HKD 1,229,241,000 in 2021 to HKD 1,091,928,000 in 2022[24] - The company’s total equity and liabilities amounted to HKD 2,697,523,000, down from HKD 2,851,160,000 in 2021, reflecting a decrease of 5.4%[24] Cash Flow and Liquidity - Cash and cash equivalents increased to HKD 1,114,456,000 in 2022 from HKD 1,027,568,000 in 2021[22] - The group maintained a strong financial position with net current assets of approximately HKD 1,090.9 million as of December 31, 2022, compared to HKD 1,163.0 million in 2021[85] - Cash and bank balances totaled approximately HKD 1,271.6 million as of December 31, 2022, up from HKD 1,203.2 million in 2021[85] - Current ratio slightly decreased to 219.1% in 2022 from 220.7% in 2021[7] Dividends - Proposed final dividend per share remains unchanged at HKD 0.086 for both 2022 and 2021[7] - The company declared a final dividend of HKD 8.6 cents per share for the year, totaling approximately HKD 71.66 million, consistent with the previous year's final dividend[55] Revenue Segments - The income from the manufacturing of injection molded components was HKD 1,673,086,000, a slight decrease from HKD 1,698,373,000 in 2021[31] - Revenue from the mold manufacturing segment was approximately HKD 606.2 million, a decline of 14.1% from HKD 706.0 million in 2021[97] - Revenue from the injection molding components manufacturing segment was approximately HKD 1,673.1 million, a slight decrease of 1.5% from HKD 1,698.4 million in 2021[99] - The mobile and wearable devices segment saw a revenue decline of 19.4%, attributed to weak demand in the personal electronics market in Europe and the US[72] - The smart home and personal care segments experienced stable growth, with revenues increasing by 7.7% and 3.6% respectively[73] - The electronic vaporizer segment's revenue grew by 27.0% year-on-year, benefiting from strong demand in the overseas market and recognition of the group's technology by international brand clients[101] Operational Efficiency - The company aims to enhance production efficiency and expects an increase in order volume and new projects as global economic recovery progresses[74] - The group is expanding its production capacity in Vietnam, with the first phase of the injection molding facility successfully launched at the end of 2021, aimed at serving electronic consumer brand clients[125] - The group is actively developing new products that integrate silicone and traditional injection molding technologies, enhancing its product offerings and competitive advantage[125] Corporate Governance - The company has adopted corporate governance policies to enhance transparency and accountability, ensuring compliance with all relevant rules and regulations[176] - The board of directors has reviewed the company's financial performance and compliance with corporate governance codes for the year ended December 31, 2022[177] - The company has implemented appropriate corporate governance measures to support its business operations and growth[176] Future Outlook - The group plans to capitalize on opportunities in the healthcare and smart home sectors, responding to China's strategy to expand domestic demand and develop new consumption models[126] - The group anticipates a moderate global economic growth in 2023, with China's reopening and policy measures boosting domestic demand[127] - The group maintains an optimistic outlook on the injection molding business, aiming for a five-year doubling of sales from 2020 levels[155] - The group will continue to seek suitable acquisition or investment targets to expand its business footprint and diversify its commercial layout[127]

東江集團(控股)有限公司 TK GROUP (HOLDINGS) LIMITED (incorporated in the Cayman Islands with limited liability) (於開曼群島註冊成立的有限公司) Stock Code 股份代號：2283 5055 INTERIM REPORT 中 期 報 告 CONTENTS 目錄 Corporate Governance and Other Information 24 企業管治及其他資料 Interim Condensed Consolidated Statement of Comprehensive Income 31 中期簡明合併綜合收益表 Interim Condensed Consolidated Balance Sheet 32 中期簡明合併資產負債表 Interim Condensed Consolidated Statement of Changes in Equity 34 中期簡明合併權益變動表 Interim Condensed Consolidated Statement of Cash Flows 36 中期 ...

(incorporated in the Cayman Islands with limited liability) 東江集團(控股)有限公司 TK GROUP (HOLDINGS) LIMITED (於閱曼群島註冊成立的有限公司) Stock Code 股份代號：2283 2021 # 報 ANNUAL REPORT CONTENTS 目錄 2 Corporate Information 公司資料 4 Financial Highlights 財務摘要 6 Chairman's Statement 主席報告書 11 Management Discussion and Analysis 管理層討論及分析 26 Directors and Senior Management 董事及高級管理層 32 Corporate Governance Report 企業管治報告 51 Environmental, Social and Governance Report 環境、社會及管治報告 84 Directors' Report 董事會報告書 103 Independent Auditor's Report 獨立核數 ...

東江集團(控股)有限公司 TK GROUP (HOLDINGS) LIMITED (incorporated in the Cayman Islands with limited liability) (於開曼群島註冊成立的有限公司) Stock Code 股份代號 : 2283 2021 INTERIM REPORT 2021 中期報告 TECHNOLOGY CONDENSES DREAMS shaping the FUTURE 科技聚萝 塑造未來 | --- | --- | --- | --- | --- | --- | |---------------------------------------------------|-------|-------|-------|-------|-------| | | | | | | | | CONTENTS 目錄 | | | | | | | | | | | | | | Corporate Information 公司資料 | 2 | | | | | | Financial Highlights | 5 | | | | | | 財務摘要 | | | | | | ...

| --- | --- | --- | --- | |---------------------------------------------------------------------------------------------------------------------------------------------------|------------------------|------------------|-------| | | | | | | TK GROUP (HOLDINGS) LIMITED (incorporated in the Cayman Islands with limited liability) (於爾曼群島註冊成立的有限公司） Stock Code 股份代號：2283 | 東江集團(控股)有限公司 | | | | | | ANNUAL REPORT 20 | | | --- | --- | --- | --- | |-------|-------|----------------|-------------------------------------- ...